期刊文献+

环孢素联合沙利度胺治疗骨髓增生异常综合征 被引量:3

下载PDF
导出
摘要 目的观察环孢素(CsA)联合沙利度胺治疗骨髓增生异常综合征(MDS)的治疗效果。方法所有MDS患者均接受司坦唑醇片基础治疗,现随机分为治疗组与对照组。对照组予以沙利度胺治疗,治疗组予以环孢素A联合沙利度胺治疗,比较两组的疗效和不良反应。结果 6个月时治疗组有效率为77.78%,对照组为64.71%,两组比较差异具有统计学意义(P<0.05)。没有发现严重的药物副作用。结论环孢素A联合沙利度胺可显著提高MDS患者的疗效且用药安全。
作者 张学军
出处 《当代医学》 2011年第3期134-135,共2页 Contemporary Medicine
  • 相关文献

参考文献5

  • 1肖志坚,郝玉书.骨髓增生异常综合征的诊断和治疗[J].中华血液学杂志,2004,25(1):61-62. 被引量:39
  • 2肖志坚,郝玉书.骨髓增生异常综合征的诊断分型与预后判断及疗效标准[J].中华内科杂志,2002,41(12):846-848. 被引量:49
  • 3Kook H,Zeng W Cuibin C,et al.lncreased cytotoxic T cell with effectors phenotype in a plastic anemia and myelodysplasia[J].Exp Hematol,2001. 29(11):1270-1277.
  • 4Asano Y,Maeda M,Uchida N,et al.lmmunosuppressive therapy for patients with refractory anemia[J].Ann Flematol.2001,80:634-638.
  • 5Bouscary D,legros L Tuiliez M,et al .A non-randomized dose-escelgting phase II study of thalidomide for the treatment of patients with low risk myelodysplastic syndromes:the Thal-SMD-2000 trial of the Group Francais des Mye Iodysplasies[J].Br J Haematol,2005,131:609-618.

二级参考文献5

  • 1Cheson BD,Bennett JM,Kantarjian H,et al.Report of an international working group to standardize response criteria for myelodysplastic syndromes[].Blood.2000
  • 2N sslinger T,Reisner R,Koller E,et al.Myelodysplastic syndromes,from French-Americam-British to World Health Organization: comprison of classification on 431 unselected patients from a single institute[].Blood.2001
  • 3Bennett JM.World Health Organization classification of the acute leukemias and myelodysplastic syndrome[].International Journal of Hematology.2000
  • 4Harris NL,Jaffe ES,Diebold T,et al.World Health Orgnization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the clinical advisory committee meeting-Airlie House,Virginia, November 1997[].Journal of Clinical Oncology.1999
  • 5Greenberg P,Cox C,LeBeau MM,et al.International scoring system for evaluating prognosis in myelodysplastic syndromes[].Blood.1997

共引文献79

同被引文献26

  • 1吴凌云,李晓,浦权.骨髓增生异常综合征的免疫治疗进展[J].新医学,2006,37(4):258-260. 被引量:11
  • 2陈书长,江滨,达万明,龚明,管梅.环孢素 A 对骨髓增生异常综合征的治疗作用研究[J].中华医学杂志,2006,86(38):2711-2715. 被引量:3
  • 3董哲,钟永明,金哈斯,李昕权.环孢素A治疗骨髓增生异常综合征临床观察[J].武警医学,2007,18(5):367-370. 被引量:1
  • 4张之南.血液病学[M].北京:人民卫生出版社,2003.1101-1106.
  • 5Raza A,Meyer P,Dutt D,et al .Thalidomide produces transfusionindependence in long-standing refractory anemias of patients with myelody-splastic syndromes[J], Blood, 2001 , 98(4). 958-965 .
  • 6Bouscary D, Legros L,Tuiliez M,et al. A non-randomised dose-escalating phase II study of thalidomide for the treatment of patients withlow-risk myelodysplastic syndromes:the Thai-SMD-2000 trial of the GroupFrancais des Myelodysplasies[J]. Br JH aematol, 2005,1 31 (5). 609-61 8.
  • 7Jonasova A, Neuwirtova R,Cermak J,et al. Cyclosporin A therapy inhypoplastic MDS patients and certain refractory anaemias without hypoplasticbone marrow[J].Br J Haemattol, 1 998,1 00(2). 304-309.
  • 8张之南;沈悌.血液诊断及疗效标准[S]北京:科技出版社,2007157-163.
  • 9Dixit A,Chatterjee T,Mishra P. Cyclosporin A in myelodysplastic syndrome:a preliminary report[J].{H}Annals of Hematology,2005,(02):565-568.
  • 10Bouscary D,Legros I,Tulliez M. A non-randomized doseescalating phaseⅡ study of thalidomide for the treat-ment of patients with low -risk myelodysplastic syn-dromes:the Tha I SMD-2000 trial of the Group Franais-des Myelodys ptasies[J].{H}British Journal of Haematology,2005,(05):609-618.

引证文献3

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部